Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Wednesday, September 30, 2015
Jaguar Animal Health, an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, has signed a four-year manufacturing and supply agreement with Glenmark ...
read more
Thursday, September 24, 2015
New offering reinforces brand commitment to efficient temperature-controlled packing solutions for the global cold chain market
read more
Thursday, September 24, 2015
CPhI Worldwide, (#cphiww) organised by UBM EMEA, today announces the finalists of the prestigious 2015 CPhI Pharma Awards. This year’s entries include innovations and new service offerings from across the entire spectrum of the pharmaceutical supply ...
read more
Wednesday, September 23, 2015
Aesica, a global pharmaceutical contract development and manufacturing organization (CDMO), is pleased to announce its involvement in a renewable green initiative involving its UK, Cramlington site.
read more
Wednesday, September 23, 2015
IDT Biologika has announced the dedication of its first U.S. vaccine manufacturing facility in Rockville, Maryland.
read more
Wednesday, September 23, 2015
The FDA is warning health care professionals about the risk for dosing errors with the intravenous antibacterial drug Avycaz (ceftazidime and avibactam) due to confusion about the drug strength displayed on the vial and carton labels.
read more
Wednesday, September 23, 2015
Intertek has opened a 10,000 ft² bioanalytical and biopharmaceutical characterization facility to deliver world-class scientific services to support the growing pipeline of biologics medicines such as monoclonal antibodies currently in development by...
read more
Wednesday, September 23, 2015
The FDA has approved trifluridine/tipiracil for the treatment of patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin- , and irinotecan-based chemotherapy, an anti-VEGF biologic product, and ...
read more
Wednesday, September 23, 2015
Huntingdon Life Sciences, Harlan Laboratories and three subsidiaries have announced that the combined companies have re-branded as Envigo.
read more
Tuesday, September 22, 2015
Xcelience and Powdersize announced today the addition of the Netzsch Delta Vita media mills, a nanoparticle milling solution, to their arsenal of capabilities. For the first time, one CDMO
can provide solutions for a full range of particle size ...
read more
Friday, September 18, 2015
On September 21, 2015, our group of companies, which presently comprises the trading companies, Huntingdon Life Sciences, Harlan Laboratories, GFA, NDA Analytics, LSR associates and various affiliates will be rebranded as Envigo (pronounced En-vee-go...
read more
Thursday, September 17, 2015
AbbVie in cooperation with Neurocrine Biosciences, Inc. has announced the completion of a Phase 2b clinical trial evaluating the safety and efficacy of elagolix alone or in combination with add-back therapy compared to placebo
read more
Thursday, September 17, 2015
Amgen and Dezima Pharma B.V. have entered into a definitive acquisition agreement under which Amgen will acquire Dezima, a privately-held, Netherlands-based biotechnology company focused on developing innovative treatments for dyslipidemia.
read more
Thursday, September 17, 2015
Impax Laboratories has announced that the FDA has approved generic Mestinon Timespan Tablets (pyridostigmine bromide extended release), 180 mg.
read more
Thursday, September 17, 2015
A newly released study has found that risk-sharing agreements (RSAs) between pharmaceutical companies and health insurers—which could significantly transform the cost and accessibility of medications—are not widely utilized in the U.S. today, but ...
read more